As of mid-September 2026, sustained low SARS-CoV-2 circulation underpins the 96.2% market-implied probability of no new coronavirus pandemic this year. WHO assessments through July describe the global public health risk as moderate, with weekly reported cases around 14,000, test positivity near 1.7%, and deaths averaging under 500 per week—sharp declines from prior years and far below pandemic thresholds. Ongoing surveillance shows no emergence of a novel, highly transmissible betacoronavirus capable of widespread severe disease, though a recently sequenced bat-derived strain with a furin cleavage site remains under study for zoonotic potential. High population immunity from prior infections and vaccination further limits escalation risk. A late-year spillover or variant shift with enhanced virulence could theoretically alter outcomes before December 31, but current epidemiological data and model trends indicate this remains improbable.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · ОновленоNew Coronavirus Pandemic in 2026?
$24,121 Обс.
$24,121 Обс.
$24,121 Обс.
$24,121 Обс.
The resolution source will be official announcements from the World Health Organization.
Ринок відкрито: Jan 6, 2026, 2:40 PM ET
Вирішувач
0x65070BE91...The resolution source will be official announcements from the World Health Organization.
Вирішувач
0x65070BE91...As of mid-September 2026, sustained low SARS-CoV-2 circulation underpins the 96.2% market-implied probability of no new coronavirus pandemic this year. WHO assessments through July describe the global public health risk as moderate, with weekly reported cases around 14,000, test positivity near 1.7%, and deaths averaging under 500 per week—sharp declines from prior years and far below pandemic thresholds. Ongoing surveillance shows no emergence of a novel, highly transmissible betacoronavirus capable of widespread severe disease, though a recently sequenced bat-derived strain with a furin cleavage site remains under study for zoonotic potential. High population immunity from prior infections and vaccination further limits escalation risk. A late-year spillover or variant shift with enhanced virulence could theoretically alter outcomes before December 31, but current epidemiological data and model trends indicate this remains improbable.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено



Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання